#185: Carvedilol superior to metoprolol in MADIT-CRT analysis; FDA approves new diabetes drug, canagliflozin, despite CV concerns; heart-smart diabetes drugs; more beaches, less bureaucracy, say burned out cardiologists

Carvedilol superior to metoprolol in MADIT-CRT analysis; FDA approves new diabetes drug, canagliflozin, despite CV concerns; heart-smart diabetes drugs; more beaches, less bureaucracy, say burned out cardiologists

Source: Radio TheHeart.org - April 5, 2013 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts